| Cytoplasmic overexpression with membrane accentuation of stratifin in intrahepatic mass-forming cholangiocarcinoma after hepatectomy: correlation with clinicopathologic features and patient survival. | |
| | |
MedLine Citation:
|
PMID: 20976731 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
PURPOSE: Cholangiocarcinoma (CCA) is a lethal malignancy that afflicts thousands of patients worldwide. Stratifin has been shown to participate in mediating G2 arrest in several cancers, and cells that express stratifin could contribute to the chemo- and radioresistance of cancers and poor prognosis. However, the clinical impact of stratifin on clinicopathological features of mass forming (MF)-CCA is still unclear. METHODS: Seventy-eight patients with MF-CCA who had undergone hepatectomy were selected for an immunohistochemical study of stratifin. Sixteen clinicopathological variables were used for the survival analyses. RESULTS: Seventy-eight MF-CCA patients (36 men and 42 women) were studied. Cytoplasmic immunostaining with membrane prominence was found in 52.6% (41/78) of patients with MF-CCA after hepatectomy; this was significantly associated with elevated carcinoembryonic antigen (CEA) levels. During the median follow-up duration of 13.6 months, the 5-year overall survival (OS) rate was 14.9%. Univariate analysis showed that an absence of clinical symptoms, better nutritional status, lower alkaline phosphatase, smaller tumor, negative lymph node metastasis, negative stratifin staining, and curative hepatic resection were associated with favorable OS rate for MF-CCA patients after hepatectomy. Multivariate Cox proportional hazard analysis showed that the absence of clinical symptoms, negative lymph node metastasis, and curative hepatectomy independently predicted MF-CCA patients with favorable OS rate after hepatectomy. CONCLUSIONS: Overexpression of stratifin was significantly associated with elevated CEA levels in patients with MF-CCA. The favorable OS for MF-CCA patients depends on the absence of clinical symptoms, negative lymph node metastasis, and curative hepatectomy. |
| | |
Authors:
|
Chun-Nan Yeh; See-Tong Pang; Shih-Ming Jung; Tsung-Wen Chen; Yi-Yin Jan; Miin-Fu Chen |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Journal of surgical oncology Volume: 102 ISSN: 1096-9098 ISO Abbreviation: J Surg Oncol Publication Date: 2010 Nov |
Date Detail:
|
Created Date: 2010-10-26 Completed Date: 2010-12-08 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0222643 Medline TA: J Surg Oncol Country: United States |
Other Details:
|
Languages: eng Pagination: 608-14 Citation Subset: IM |
Affiliation:
|
Department of Surgery, Chang Gung Memorial Hospital, Chang Gung University, Taoyuan, Taiwan. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
14-3-3 Proteins
/
metabolism* Aged Bile Duct Neoplasms / metabolism*, mortality, surgery Bile Ducts, Intrahepatic* Carcinoembryonic Antigen / metabolism Cell Membrane / metabolism Cholangiocarcinoma / metabolism*, mortality*, surgery Cytosol / metabolism Exonucleases / metabolism* Female Hepatectomy Humans Liver Neoplasms / metabolism*, mortality, pathology, surgery Lymphatic Metastasis Male Middle Aged Tumor Markers, Biological / metabolism* |
| Chemical | |
Reg. No./Substance:
|
0/14-3-3 Proteins; 0/Carcinoembryonic Antigen; 0/Tumor Markers, Biological; EC 3.1.-/Exonucleases; EC 3.1.-/SFN protein, human |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Surgical management in metastatic gastrointestinal stromal tumor (GIST) patients after imatinib mesy...
Next Document: Safety of sentinel node biopsy in breast cancer patients who receive a second radioisotope injection...